Sort   by:  
 Page size 
MetabolomicsMolecular networking coupled to high-resolution mass spectrometry fragmentation reveals a multitude of urinary antihypertensive drug metabolites
Mass spectrometry is the current technique of choice in studying drug metabolism. High-resolution mass spectrometry (HR-MS) in combination with fragment analysis (MS/MS) has the potential to contribute to rapid advances in this field. However, the data emerging from such fragmentation spectra pose c...
2016-05-23 | MTBLS307 | MetaboLights
MetabolomicsConsistency across multi-omics layers in a drug-perturbed gut microbial community
Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the comm...
2022-12-08 | MTBLS3129 | MetaboLights
MetabolomicsMetabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights
MetabolomicsTranscriptional Shift and Metabolic Adaptations during Leishmania Quiescence Using Stationary Phase and Drug Pressure as Models

Microorganisms can adopt a quiescent physiological condition which acts as a survival strategy under unfavourable conditions. Quiescent cells are characterized by slow or non-proliferation and deep down-regulation of processes related to biosynthesis. Although quiescence has been described mostly...

2022-02-23 | MTBLS4046 | MetaboLights
MetabolomicsClinical Application Value of Ceramide and Sphingomyelin as Biomarkers for the Diagnosis of Drug-Induced Liver Injury

Background : Drug-induced liver injury (DILI) is a serious health concern that presents challenges in early detection and accurate diagnosis, thereby complicating the treatment of this liver disease. Therefore, it is crucial to explore specific biomarkers to improve the accuracy of diagnosing DIL...

2025-07-23 | MTBLS12765 | MetaboLights
MetabolomicsMetabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery
Psoriasis is a chronic skin disease that affects multiple systems and can be influenced by immunological, environmental, and genetic factors. The discovery of plasma biomarkers of psoriasis and the regulation of metabolic pathways helps us understand psoriasis and may assist clinicians in the diagno...
2024-09-26 | MTBLS5185 | MetaboLights
MetabolomicsMetabolic impacts of metformin to seasonal influenza vaccination: a pilot study of drug interaction with the immune response
Not available
ORGANISM(S): Homo sapiens 
ST002432 | MetabolomicsWorkbench
MetabolomicsInvestigation of the threonine metabolism of Echinococcus multilocularis: EmTDH as a potential drug target in alveolar echinococcosis
Alveolar echinococcosis is a severe zoonotic disease caused by the fox tapeworm E. multilocularis. New treatment options are urgently needed. Whole-organism-based screening allows the discovery of potential new anti-echinococcal compounds, but suffers from low- to medium-throughput. An alternative a...
2026-09-14 | MTBLS10738 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (B.animalis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1264 | MetaboLights
TranscriptomicsGenetic and molecular basis of drug resistance and species-specific drug action in Schistosome parasites
Oxamniquine resistance evolved in the human blood fluke (Schistosoma mansoni) in Brazil in the 1970s. We crossed parental parasites differing ~500-fold in drug response, determined drug sensitivity and marker segregation in clonally-derived F2s, and identified a single QTL (LOD=31) on chromosome 6. ...
ORGANISM(S): Schistosoma mansoni 
2013-12-05 | E-GEOD-51847 | biostudies-arrayexpress
Sort   by:  
 Page size